NASH patients have higher plasma levels of IL-17A and IL-23 cytokines compared to CHC with significant fibrosis and cirrhosis, as well as serum and tissue IL-17A compared to CHC without significant fibrosis but with same stages of fibrosis, reflecting probable higher systemic multifactorial inflammation in NASH compared to CHC. This evidence concerns the gene IL23A and fibrosis.